SCHEMBL2874006

SCHEMBL2874006

COC(=O)c1cc(CBr)ccc1NC(=O)c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 8/20 0.50
KMT2A Q03164 4/20 0.50
KLKB1 P03952 2/20 0.49
HPGD P15428 3/20 0.48
HSD17B10 Q99714 1/20 0.48
KDM4E B2RXH2 3/20 0.48
NPSR1 Q6W5P4 1/20 0.48
MEN1 O00255 2/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
ALDH1A1 P00352 3/20 0.47
POLB P06746 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP2C19 P33261 2/20 0.46
NPC1 O15118 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
RAB9A P51151 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3050158 0.87 POLB (0.56) KMT2AHPGDHSD17B10KDM4EMEN1
SCHEMBL2876056 0.85 F10 (0.50) F10KMT2AKLKB1HPGDHSD17B10
SCHEMBL2878827 0.82 KDM4E (0.61) F10KMT2AHPGDKDM4ENPSR1
SCHEMBL9337435 0.79 TSHR (0.68) KMT2AHPGDHSD17B10KDM4ENPSR1
SCHEMBL417476 0.79 SERPINE1 (0.56) F10KMT2AHPGDHSD17B10KDM4E
SCHEMBL1826967 0.78 HTT (0.48) KMT2AHPGDHSD17B10KDM4ENPSR1
SCHEMBL3619892 0.77 KMT2A (0.67) KMT2AHPGDHSD17B10KDM4ENPSR1
SCHEMBL21682955 0.77 GAA (0.67) KMT2AHPGDHSD17B10KDM4ELMNA
SCHEMBL23635269 0.76 KDM4E (0.63) KMT2AHPGDHSD17B10KDM4EMEN1
SCHEMBL844331 0.75 CYP4F2 (0.72) KMT2AHPGDHSD17B10KDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1768984-B1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS SUNESIS PHARMACEUTICALS INC (US) 2010-10-20 EP disclosed
US-20100179123-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2010-07-15 US disclosed
US-7601725-B2 Thienopyrimidines useful as Aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2009-10-13 US disclosed
EP-1768984-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS Sunesis Pharmaceuticals, Inc. (US) 2007-04-04 EP disclosed
WO-2006036266-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2006-04-06 WO disclosed
US-20060035908-A1 Thienopyrimidines useful as Aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179123-A1 THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS AURKA, AURKB, AURKC F10 2950/4885KMT2A 529/4885KLKB1 1091/4885
US-20060035908-A1 Thienopyrimidines useful as Aurora kinase inhibitors AURKA, AURKB, AURKC F10 3109/4885KMT2A 551/4885KLKB1 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.